期刊文献+

肺癌患者口服特罗凯致皮疹的观察与护理 被引量:6

肺癌患者口服特罗凯致皮疹的观察与护理
下载PDF
导出
摘要 皮疹是特罗凯治疗非小细胞肺癌(NSCLC)的常见副作用之一,本文观察19例口服特罗凯的肺癌患者,其中18例患者出现了不同程度的皮疹,且皮疹的严重程度、部位有较大差异。在临床护理实践中,加强患者教育,告知患者药物皮疹的相关知识,及时发现和处理皮疹,能避免和减少药物严重副作用,从而提高治疗效果及患者生活质量。
出处 《临床护理杂志》 2008年第5期24-25,共2页 Journal of Clinical Nursing
关键词 疹/病因学 疹/护理 特罗凯 exanthema/etiology exanthema/nursing tarceva
  • 相关文献

参考文献1

二级参考文献22

  • 1[1]Lynch TJ Jr,Kim ES,Eaby B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:An evolving paradigm in clinical management.Oncologist,2007,12 (5):610
  • 2[2]Lacouture ME.Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer,2006,6 (10):803
  • 3[3]Agero AL,Dusza SW,Benvenuto-Andrade C,et al.Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol,2006,55(4):657
  • 4[4]Rhee J,Oishi K,Garey J,et al.Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.Clin Colorectal Cancer,2005,5(Suppl 2):S101
  • 5[5]Molinari E,De Quatrebarbes J,Andre T,et al.Cetuximab-induced acne.Dermatology,2005,211 (4):330
  • 6[6]Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol,2004,22 (16):3238
  • 7[7]Robert C,Soria JC,Spatz A,et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies.Lancet Oncol,2005,6 (7):491
  • 8[8]Segaert S,Van Cutsem E.Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.Ann Oncol,2005,16(9):1425
  • 9[9]Jost M,Kari C,Rodeck U.The EGF receptor:An essential regulator of multiple epidermal functions.Eur J Dermatol,2000,10 (7):505
  • 10[10]Mimeault M,Bonenfant D,Batra SK.New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation,disorders and cancers.Skin Pharmacol Physiol,2004,17 (4):153

共引文献19

同被引文献32

  • 1储大同.肿瘤分子靶向治疗的进展及问题[J].临床肿瘤学杂志,2006,11(1):1-6. 被引量:24
  • 2Robert C,Soria JC,Spatz A,et al. Cutaneous side- efects of kinase inhibitors and blocking antibodies[J]. Lancet Oncol,2005,6:491 -500.
  • 3Wood LS. Managing the side effects of sorafenib and sunitinib[ J]. Commun Oncol,2006,3:5558 - 624.
  • 4Cheng AL,Kang YK,Chen Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trim [ J ]. Lancet Oncol,2009,10 ( 1 ) :25 - 34.
  • 5Wood LS. Managing the side effects of sorafenib and sunitinib [ J ]. Commun Onco1,2006 ,3 :558 - 62.
  • 6ROBERT C,SOFIA JC,SPIN A,et al.Cutaneous -efects of inase inhibitors and blocking antibodies[J].Lancet Oncol,2005,6:491.
  • 7WOOD LS.Managing the side effects of sorafenib and sunitinib[J].Commun Oncol,2006,3:558.
  • 8杰伊A利维.艾滋病病毒与艾滋病的发病机制[M].北京:科学出版社,2000.25-26.
  • 9Tang PA, Tsao MS, MooreMJ. A review of erlotinib and its clinical use[ J ]. Expert Opin Phamracother,2006,7 (2) : 177 - 193.
  • 10Perez Soler R, Chachoua A, Hammond LA,et al. Determinants of tumor response and survival with crlotinib in patients with non - small cell lung cancer[J]. J Clin Oncol,2004,22 (16) :3238 - 3247.

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部